12:00 AM
 | 
Sep 03, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

RVX-208: Phase IIb data

Top-line data from the double-blind, South African Phase IIb SUSTAIN trial in 176 patients with atherosclerotic cardiovascular disease and low HDL-C who were receiving statin therapy showed that twice-daily 100 mg oral RVX-208 met the primary endpoint of increasing HDL-C from baseline to week 24 vs. placebo...

Read the full 212 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >